Cargando…

Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium

BACKGROUND: The prognosis for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the inferior vena cava (IVC) or right atrium (RA) is poor, and there is no established effective treatment for this condition. Thus study aimed to evaluate the efficacy of surgical resection and prognosis aft...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakayama, Kenji, Kamiyama, Toshiya, Yokoo, Hideki, Kakisaka, Tatsuhiko, Kamachi, Hirofumi, Tsuruga, Yosuke, Nakanishi, Kazuaki, Shimamura, Tsuyoshi, Todo, Satoru, Taketomi, Akinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851861/
https://www.ncbi.nlm.nih.gov/pubmed/24093164
http://dx.doi.org/10.1186/1477-7819-11-259
_version_ 1782294369438531584
author Wakayama, Kenji
Kamiyama, Toshiya
Yokoo, Hideki
Kakisaka, Tatsuhiko
Kamachi, Hirofumi
Tsuruga, Yosuke
Nakanishi, Kazuaki
Shimamura, Tsuyoshi
Todo, Satoru
Taketomi, Akinobu
author_facet Wakayama, Kenji
Kamiyama, Toshiya
Yokoo, Hideki
Kakisaka, Tatsuhiko
Kamachi, Hirofumi
Tsuruga, Yosuke
Nakanishi, Kazuaki
Shimamura, Tsuyoshi
Todo, Satoru
Taketomi, Akinobu
author_sort Wakayama, Kenji
collection PubMed
description BACKGROUND: The prognosis for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the inferior vena cava (IVC) or right atrium (RA) is poor, and there is no established effective treatment for this condition. Thus study aimed to evaluate the efficacy of surgical resection and prognosis after surgery for such cases. METHODS: Between January 1990 and December 2012, 891 patients underwent hepatectomy for HCC at our institution. Of these, 13 patients (1.5%) diagnosed with advanced HCC with tumor thrombi in the IVC or RA underwent hepatectomy and thrombectomy. Data detailing the surgical outcome were evaluated and recurrence-free and overall survival rates were calculated using the Kaplan-Meier method. RESULTS: Seven patients had an IVC thrombus and six had an RA thrombus. Extra-hepatic metastasis was diagnosed in 8 of 13 patients. Surgical procedures included three extended right lobectomies, three extended left lobectomies, five right lobectomies, and two sectionectomies. Right adrenal gland metastases were excised simultaneously in two patients. All IVC thrombi were removed under hepatic vascular exclusion and all RA thrombi were removed under cardiopulmonary bypass (CPB). Four patients (30.8%) experienced controllable postoperative complications, and there was no surgical mortality. The mean postoperative hospital stay for patients with IVC and RA thrombi was 23.6 ± 12.5 days and 21.2 ± 4.6 days, respectively. Curative resection was performed in 5 of 13 cases. The 1- and 3-year overall survival rates were 50.4%, and 21.0%, respectively, and the median survival duration was 15.3 months. The 1- and 3-year overall survival rates for patients who underwent curative surgical resection were 80.0% and 30.0%, respectively, with a median survival duration of 30.8 months. All patients who underwent curative resection developed postoperative recurrences, with a median recurrence-free survival duration of 3.8 months. The 1-year survival rate for patients who underwent noncurative surgery and had residual tumors was 29.2%, with a median survival duration of 10.5 months. CONCLUSIONS: Aggressive surgical resection for HCC with tumor thrombi in the IVC or RA can be performed safely and may improve the prognoses of these patients. However, early recurrence and treatment for recurrent or metastatic tumors remain unresolved issues.
format Online
Article
Text
id pubmed-3851861
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-38518612013-12-06 Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium Wakayama, Kenji Kamiyama, Toshiya Yokoo, Hideki Kakisaka, Tatsuhiko Kamachi, Hirofumi Tsuruga, Yosuke Nakanishi, Kazuaki Shimamura, Tsuyoshi Todo, Satoru Taketomi, Akinobu World J Surg Oncol Research BACKGROUND: The prognosis for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the inferior vena cava (IVC) or right atrium (RA) is poor, and there is no established effective treatment for this condition. Thus study aimed to evaluate the efficacy of surgical resection and prognosis after surgery for such cases. METHODS: Between January 1990 and December 2012, 891 patients underwent hepatectomy for HCC at our institution. Of these, 13 patients (1.5%) diagnosed with advanced HCC with tumor thrombi in the IVC or RA underwent hepatectomy and thrombectomy. Data detailing the surgical outcome were evaluated and recurrence-free and overall survival rates were calculated using the Kaplan-Meier method. RESULTS: Seven patients had an IVC thrombus and six had an RA thrombus. Extra-hepatic metastasis was diagnosed in 8 of 13 patients. Surgical procedures included three extended right lobectomies, three extended left lobectomies, five right lobectomies, and two sectionectomies. Right adrenal gland metastases were excised simultaneously in two patients. All IVC thrombi were removed under hepatic vascular exclusion and all RA thrombi were removed under cardiopulmonary bypass (CPB). Four patients (30.8%) experienced controllable postoperative complications, and there was no surgical mortality. The mean postoperative hospital stay for patients with IVC and RA thrombi was 23.6 ± 12.5 days and 21.2 ± 4.6 days, respectively. Curative resection was performed in 5 of 13 cases. The 1- and 3-year overall survival rates were 50.4%, and 21.0%, respectively, and the median survival duration was 15.3 months. The 1- and 3-year overall survival rates for patients who underwent curative surgical resection were 80.0% and 30.0%, respectively, with a median survival duration of 30.8 months. All patients who underwent curative resection developed postoperative recurrences, with a median recurrence-free survival duration of 3.8 months. The 1-year survival rate for patients who underwent noncurative surgery and had residual tumors was 29.2%, with a median survival duration of 10.5 months. CONCLUSIONS: Aggressive surgical resection for HCC with tumor thrombi in the IVC or RA can be performed safely and may improve the prognoses of these patients. However, early recurrence and treatment for recurrent or metastatic tumors remain unresolved issues. BioMed Central 2013-10-05 /pmc/articles/PMC3851861/ /pubmed/24093164 http://dx.doi.org/10.1186/1477-7819-11-259 Text en Copyright © 2013 Wakayama et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wakayama, Kenji
Kamiyama, Toshiya
Yokoo, Hideki
Kakisaka, Tatsuhiko
Kamachi, Hirofumi
Tsuruga, Yosuke
Nakanishi, Kazuaki
Shimamura, Tsuyoshi
Todo, Satoru
Taketomi, Akinobu
Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
title Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
title_full Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
title_fullStr Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
title_full_unstemmed Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
title_short Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
title_sort surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851861/
https://www.ncbi.nlm.nih.gov/pubmed/24093164
http://dx.doi.org/10.1186/1477-7819-11-259
work_keys_str_mv AT wakayamakenji surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT kamiyamatoshiya surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT yokoohideki surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT kakisakatatsuhiko surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT kamachihirofumi surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT tsurugayosuke surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT nakanishikazuaki surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT shimamuratsuyoshi surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT todosatoru surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium
AT taketomiakinobu surgicalmanagementofhepatocellularcarcinomawithtumorthrombiintheinferiorvenacavaorrightatrium